XSXuexia Shan

Xuexia Shan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuexia Shan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Hui-Xiong Xu

    Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China

    2 shared publications
  • Li-Ping Sun

    Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China

    2 shared publications
  • Shaoyue Li

    Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, P. R. China

    2 shared publications
  • Shuo Liu

    Department of Medical Ultrasound Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai P. R. China

    2 shared publications
  • Weiwei Ren

    Department of Medical Ultrasound Center of Minimally Invasive Treatment for Tumor Shanghai Tenth People's Hospital School of Medicine Tongji University Shanghai P. R. China

    2 shared publications
  • Wenwen Yue

    Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation

    by Xuexia Shan, Yuting Shen, Xiaodong Hou, Fengshan Jin, Shaoyue Li, Weichen Xu, Weiwei Ren, Xiaowan Bo, Qiuyan Li, Shuo Liu, et al.

    Microwave ablation (MWA) is an effective locoregional therapy for solid tumors, but recurrence caused by minimal residual disease remains a clinical challenge. Although immunotherapy offers a strategy to prevent recurrence, the role of tumor‐draining lymph nodes (TDLNs) in post‐ablation immune regulation remains underexplored. Here, single‐cell RNA sequencing (scRNA‐seq) reveals pronounced macrophage remodeling in TDLNs following incomplete MWA (iMWA), characterized by an increased representation of immunosuppressive Folr2 + and Apoe + macrophage subsets. These populations exhibit broad colony‐stimulating factor 1 receptor ( Csf1r ) expression, accompanied by enhanced CSF signaling and macrophage‐centered intercellular communication, implicating CSF1R‐associated macrophage remodeling in post‐ablation immunosuppression. Accordingly, an albumin‐based lipoprotein nanosystem co‐encapsulating paclitaxel (PTX) and the CSF1R inhibitor BLZ945 (PTX/BLZ945@Alb‐lip) was developed. Across multiple tumor models, PTX/BLZ945@Alb‐lip enhances immunomodulator delivery to both TDLNs and tumors, remodels the macrophage‐mediated immunosuppressive microenvironment, and suppresses residual tumor growth after iMWA. Moreover, treatment promotes durable antitumor immune memory and protects cured mice against tumor rechallenge. These findings identify TDLNs as an important therapeutic site in post‐ablation immunotherapy and provide a potential strategy to prevent tumor recurrence following ablation.

  • Open Access

    Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation

    by Weichen Xu, Shaoyue Li, Xuexia Shan, Qiao Wang, Xinhua Chen, Shengbo Wu, Yincheng Gao, Dandan Shan, Shisi Ding, Weiwei Ren, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.